Menu
We are a translational lab focusing on pancreatic cancer research and specifically on BRCA-mutated PDAC. We are studying resistance mechanisms, response to treatment and develop novel treatments. We are using in vivo models that recapitulate the clinical scenario, perform deep genomics analysis. We have a large biobank of samples from PDAC patients and high-risk individuals.
The best treatment option for PDAC is tumor removal at earliest stage possible, however this is very challenging due to its late clinical manifestation. Therefore early detection is an emergent need. Utilization of cfNDA for multi-omics analysis has a potential for development of a multi-level signature that can be especially useful for high risk populaitons.
We will develop a signature based on somatic mutations specific to PDAC, such as KRAS, tp53, etc in order to use this signature for identification of early PDAC onset in cfDNA.
Copyright 2023 LIQUIDBXÂ – All Rights Reserved
Produced by Webzilla